|
KMID : 0338420190340051107
|
|
Korean Journal of Internal Medicine
2019 Volume.34 No. 5 p.1107 ~ p.1115
|
|
|
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
|
|
Kim Moon-Jin
Kim Sung-Min
Jung Hyun-Ae
Hong Jung-Yong
Chang Won-Jin
Choi Moon-Ki
Kim Hye-Sook
Sun Jong-Mu
Park Keun-Chil
Ahn Myung-Ju
|
|
|
Abstract
|
|
|
Background/Aims: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Methods: In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks.
Results: Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality.
Conclusions: For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment.
|
|
|
KEYWORD
|
|
|
Cisplatin, Docetaxel, Head and neck neoplasms, Carcinoma, squamous cell
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|
|